Rationally Designed Peptide Immunotherapy for Peanut Allergy: Bringing Antigen-Specific Immune Tolerance into Late-Stage Clinical Reality
- Exploring Aravax’s peptide-based immunotherapy that is designed to induce antigenspecific immune tolerance by precisely targeting T-cells
- Delving into the translational strategy that has led to late phase II clinical trials
NEW DATA